| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Cacilda S. Souza | Q55590555 |
| P2093 | author name string | Ricardo Romiti | |
| Luana Pizarro Meneghello | |||
| Cacilda da Silva Souza | |||
| André Vicente Esteves de Carvalho | |||
| Renato Soriani Paschoal | |||
| Laura de Mattos Milman | |||
| P2860 | cites work | Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 |
| Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) | Q28280465 | ||
| Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet | Q28574910 | ||
| The metabolic syndrome--a new worldwide definition | Q29615125 | ||
| Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure | Q33611681 | ||
| Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers | Q33659058 | ||
| Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. | Q33823950 | ||
| Psoriasis and hypertension severity: results from a case-control study | Q33867611 | ||
| Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis | Q34327755 | ||
| Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months | Q34346418 | ||
| Chronic TNF-α Neutralization Does Not Improve Insulin Resistance or Endothelial Function in “Healthy” Men with Metabolic Syndrome | Q34699554 | ||
| Psoriasis and Metabolic Syndrome--scientific evidence and therapeutic implications | Q35045850 | ||
| The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. | Q35135831 | ||
| Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis | Q35638180 | ||
| Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom | Q35753936 | ||
| Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis | Q35954510 | ||
| Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis | Q36204149 | ||
| Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs | Q36361147 | ||
| The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk | Q36698765 | ||
| Rheumatoid cachexia: a clinical perspective | Q37151582 | ||
| A comparison of vascular inflammation in psoriasis, rheumatoid arthritis, and healthy subjects by FDG-PET/CT: a pilot study | Q37285410 | ||
| Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis | Q37394857 | ||
| A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis | Q37728928 | ||
| Can early treatment with biologicals modify the natural history of comorbidities? | Q37736578 | ||
| Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions | Q37743164 | ||
| Systematic review and meta‐analysis: Anti–tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis | Q37801353 | ||
| Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review | Q37808889 | ||
| Metabolic comorbidities and psoriasis. | Q37830809 | ||
| Obesity and psoriasis: body weight and body mass index influence the response to biological treatment | Q37865060 | ||
| The association between psoriasis and dyslipidaemia: a systematic review | Q38056160 | ||
| Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations | Q38264287 | ||
| Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities | Q38269971 | ||
| Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis | Q41951968 | ||
| Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model | Q42509579 | ||
| Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. | Q42613896 | ||
| Hypoglycaemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus | Q42735592 | ||
| Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study | Q44398860 | ||
| Association between pediatric psoriasis and the metabolic syndrome | Q44905505 | ||
| Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus | Q45288103 | ||
| Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. | Q45761302 | ||
| Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease | Q46085890 | ||
| Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis | Q46538689 | ||
| Infliximab, a TNF-α inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patients | Q46598130 | ||
| Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody | Q46757443 | ||
| Effect of etanercept on insulin sensitivity in nine patients with psoriasis | Q46819537 | ||
| The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet | Q46860893 | ||
| Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis | Q46987065 | ||
| The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial | Q47177526 | ||
| Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. | Q47261263 | ||
| Body weight increment in patients treated with infliximab for plaque psoriasis. | Q47308544 | ||
| Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu | Q47849023 | ||
| Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). | Q47945239 | ||
| Severe hypoglycemia after initiation of anti-tumor necrosis factor therapy with etanercept in a patient with generalized pustular psoriasis and type 2 diabetes mellitus | Q47954530 | ||
| Inhibition of TNF-α in hypothalamic paraventricular nucleus attenuates hypertension and cardiac hypertrophy by inhibiting neurohormonal excitation in spontaneously hypertensive rats | Q48541426 | ||
| The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. | Q51350319 | ||
| Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. | Q51366532 | ||
| Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study. | Q51367005 | ||
| Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. | Q51501693 | ||
| Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study. | Q51695204 | ||
| Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. | Q54176069 | ||
| Assessor-blinded study of the metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared with age-matched population of children with warts. | Q54352411 | ||
| Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH) | Q57646565 | ||
| Prevalence of cardiovascular risk factors in patients with psoriasis | Q60711908 | ||
| Elevated circulating levels of tumor necrosis factor in severe chronic heart failure | Q68524243 | ||
| Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis | Q79610823 | ||
| Unstable diabetes in a patient receiving anti-TNF-alpha for rheumatoid arthritis | Q80336021 | ||
| Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study | Q80439172 | ||
| Association between psoriasis and the metabolic syndrome. A cross-sectional study | Q80541738 | ||
| Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis | Q80657531 | ||
| Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? | Q80800883 | ||
| Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes | Q80970294 | ||
| [I Brazilian guidelines on diagnosis and treatment of metabolic syndrome] | Q81046986 | ||
| Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis | Q81050476 | ||
| Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis | Q81397478 | ||
| Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL) | Q84528015 | ||
| Anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis | Q85264043 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | psoriasis | Q179945 |
| monoclonal antibody | Q422248 | ||
| comorbidity | Q1414874 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 781-789 | |
| P577 | publication date | 2016-11-01 | |
| P1433 | published in | Anais Brasileiros de Dermatologia | Q15750855 |
| P1476 | title | Psoriasis comorbidities: complications and benefits of immunobiological treatment | |
| P478 | volume | 91 |
| Q89981658 | Analysis of cardiovascular risk and carotid intima-media thickness in patients with psoriasis |
| Q64921248 | Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative. |
| Q89810854 | Hyperproliferation is the main driver of metabolomic changes in psoriasis lesional skin |
| Q55025008 | MiR-146a G/C rs2910164 variation in South African Indian and Caucasian patients with psoriatic arthritis. |
| Q64245109 | Recommendations for Initiating Systemic Therapy in Patients with Psoriasis |
Search more.